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There are 2 topoisomerase II isozymes. Topoisomerase II α, highly expressed in cancer cells and required for cell division, is the target for anthracycline's antitumor effect.
12,13 However, adult cardiomyocytes express only topoisomerase II β, which is not required for cell division. 14 Since dexrazoxane binds to topoisomerase II β and inhibits doxorubicin-induced DNA double-strand break, it is likely that doxorubicin causes cardiotoxic effects by targeting topoisomerase II β. We generated a mouse model in which topoisomerase II β could be genetically deleted in adult cardiomyocytes and showed that both doxorubicin-induced DNA double-strand breaks and apoptosis were blunted.
15
Doxorubicin also causes a profound change in the transcriptome of cardiomyocytes because topoisomerase II β/doxorubicin binds to selective promoters to regulate gene transcription. Key antioxidative enzymes are reduced following doxorubicin treatment only in cardiomyocytes with intact topoisomerase II β. This explains why doxorubicin-induced ROS production is dependent on topoisomerase II β. Interestingly, peroxisome proliferatoractivated receptor-γ coactivator1α (PGC1α) and PGC1β, 2 key transcription factors important to mitochondrial biogenesis, are also decreased in the doxorubicin-treated cardiomyocytes. As a result, mitochondrial electron transport proteins are decreased. Electron microscopy of heart samples showed classic histological changes in the mitochondria of cardiomyocytes treated with doxorubicin, but not in topoisomerase II β-depleted cardiomyocytes. Together, these findings show that topoisomerase II β is the molecular basis of anthracycline-induced cardiotoxic effects. This new paradigm retains the old observation of doxorubicin-induced ROS generation and mitochondriopathy but explains them in terms of topoisomerase II β (Figure) . 15, 16 The identification of topoisomerase II β as the molecular basis of anthracycline-induced cardiotoxic effects leads to 3 useful predictions. First, a new anthracycline specific for topoisomerase II α, but not for topoisomerase II β, should have antitumor activity but no cardiotoxic effects. Second, determining a patient's topoisomerase II β expression level may be useful in predicting the patient's susceptibility to anthracycline-induced cardiotoxic effects before chemotherapy is initiated. Finally, inhibition of topoisomerase II β should be the most effective strategy to prevent anthracyclineinduced cardiotoxic effects. 17 However, an early clinical trial showed that patients who received dexrazoxane and doxorubicin had reduced objective response rate, but time to progression and survival were not different compared with placebo and doxorubicin. 19 New York Heart Association class 3 or 4 heart failure was observed in 27% of patients receiving anthracycline, cyclophosphamide, and trastuzumab; in 8% of patients given an anthracycline or cyclophosphamide alone; in 13% of patients given combined paclitaxel and trastuzumab; and in 1% of patients given paclitaxel alone. Thus, trastuzumab can induce cardiotoxic effects by itself, and the severity of these effects is compounded by concomitant use of anthracycline. 19 The alarming incidence of cardiotoxic effects prompted a call to more cautious use of trastuzumab.
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The high incidence of heart failure in the metastatic breast cancer trial 19 prompted institution of intensive cardiac monitoring in the subsequent adjuvant trials. Newer clinical trials 25 avoiding concomitant use of anthracycline and trastuzumab had much lower incidences of heart failure. The manifestation of cardiotoxic effects is different between anthracyclines and trastuzumab. Cardiac biopsy of trastuzumab-treated patients did not reveal the classic changes of myofibril disarray and mitochondriopathy associated with anthracycline cardiotoxic effects. Clinically, trastuzumab-induced cardiotoxic effects also differ from anthracycline-induced cardiotoxic effects. In contrast to cardiotoxic effects induced by anthracycline, trastuzumab-induced cardiotoxic effects is not dose-related; it is often reversible with cessation of therapy and initiation of conven- of patients treated with imatinib showed that, of 1276 patients, only 22 (1.7%) developed systolic heart failure; of these 22 patients, 11 continued to receive imatinib therapy with dose adjustments and were monitored for CHF symptoms without further complications. Thus, the initial report of potential cardiotoxic effects of TKIs needs to be validated by larger clinical trials, and early identification of toxicity or dose-reduction may allow a lifesaving drug to remain on the market.
36
Sunitinib, approved for treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors, caused hypertension in 47% of treated patients and CHF in 8% in a small study 37 of 75 patients. In a larger meta-analysis 38 of 6935 patients, the incidence of all-grade and high-grade CHF in patients treated with sunitinib was 4.1% and 1.5%, respectively. Congestive heart failure was reversible by withholding sunitinib therapy and/or initiation of heart failure therapy in 56% of patients in a retrospective adjudication of comprehensive cardiovascular adverse events from 2 phase 3 trials. 39 Sunitinib is a multikinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors, and plateletderived growth factor receptors (PDGFRs). Thus, it is not surprising that hypertension can result from inhibition of multiple receptors involved in the homeostasis of the vasculature. 40 In an animal model, PDGFR-β is required for cardiomyocytes to respond to stress-induced cardiac angiogenesis. 41 Mice that underwent cardiomyocyte-specific deletion of PDGFR-β developed heart failure when exposed to load-induced stress, such as hypertension. Thus, hypertension and heart failure caused by sunitinib and other TKIs that target the VEGF signaling pathway can be explained mechanistically and prevented by aggressive treatment of hypertension.
42
Recently, ponatinib (iclusig), a TKI approved for imatinibresistant chronic myelogenous leukemia, was pulled from the market temporarily owing to a 27% incidence of arterial and venous thrombosis or occlusion. 43 However, ponatinib was shown to inhibit platelet aggregate formation in whole blood under shear stress. 44 Similar to ponatinib, nilotinib has also been associated with increased incidence of arterial and venous thrombosis. Further studies are needed to clarify the mechanism of action contributing to accelerated atherosclerosis and thromboembolism in patients treated with ponatinib and nilotinib. Regardless of the mechanism of vascular toxic effects, careful modification of cardiac risk factors and close follow-up are required in patients treated with selected TKIs, especially TKIs targeting the VEGF signaling pathway. 40 It is clear that the off-target effects of TKIs provide an opportunity for both basic and translational research in our field.
An Emerging Field: Cardiologist Collaborating With Oncologist
The use of targeted therapy in the past 15 years has converted several cancers from a terminal illnesses to a chronic diseases, vastly increasing the number of cancer survivors. In 2012, there were 12 million cancer survivors in the United States. This number is estimated to double by the end of the next decade. 45 Among cancer survivors, half will die of cancer recurrence, but a third will die of cardiovascular disease. Thus, the need for optimal cardiac care in the cancer population has become evident. Chemotherapy can cause myriad cardiovascular complications, including hypertension, CHF, thromboembolic diseases, ischemic heart disease, QT prolongation, and bradycardia. 46 Radiation therapy can cause acute complications, such as pericarditis and long-term complications, such as accelerated coronary artery disease, valvular disease, and restrictive or constrictive pericarditis. 47 Thus, cardiologists could play a pivotal role in the care of cancer patients undergoing chemotherapy and/or radiation therapy. Early detection of cardiotoxic effects requires timely imaging studies and monitoring with biomarkers. Determining left ventricular ejection fraction (LVEF) with the use of noninvasive techniques, such as echocardiography or multiple gated acquisition (MUGA) scanning, during chemotherapy is recommended by all guidelines.
48,49
Because of radiation exposure, echocardiography is generally preferred in cardiac monitoring over MUGA scanning. In a large population-based study 50 of patients diagnosed with breast cancer aged 66 years or older, adequate cardiac monitoring was obtained in only 36% of patients. In a retrospective study, 51 early detection of LVEF 52 Further studies are required to determine the best frequency of monitoring during chemotherapy.
In the past decade, cardiologists have carried out multiple small clinical studies with drugs used in heart failure therapy, such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers, or β-blockers (BB), to provide either primary or secondary prevention for anthracycline-induced cardiotoxic effects. [53] [54] [55] [56] Many of these studies showed benefit; however, the short-term benefits may have been owing to changes in hemodynamics, not a result of true cardioprotection. Larger and more long-term clinical studies are required to demonstrate true efficacy. This is important because in a pediatric study, the short-term benefit of ACEIs disappeared with long-term follow-up. 57 However, ACEIs in this study may not show efficacy because the drug was started a median of 8 years after chemotherapy. Taken together, the best evidence for primary prevention of anthracycline-induced cardiotoxic effects is dexrazoxane based on its mechanism of action. 11,15 At present, ACEIs, BB, aldosterone antagonists, or statin cannot be recommended in primary prevention owing to insufficient evidence. Because cancer is usually a criterion for exclusion in cardiovascular trials, there is a paucity of evidence-based recommendations for diagnosing, preventing, and treating cancer therapy-induced cardiovascular complications. A number of guidelines have been published, based primarily on a consensus of committee members. 48, 49 However, these guidelines are not routinely followed by clinicians. We must carry out clinical studies and establish registries to address specific issues that are pertinent to our unique practice rather than relying on consensus or inadequate clinical studies. Furthermore, oncocardiology is not limited to clinical studies; basic research exemplified by the discovery of the molecular target for anthracycline-induced cardiotoxic effects provides a new playing field for physicians and scientists. 15 The National Institutes of Health has conducted a workshop, published a white paper, and established a funding mechanism (PA-16-035, PA-16-036) for the study of basic and clinical research relevant to oncocardiology. 58 In a study 59 of childhood cancer survivors, the overall mortality ratio was 8.3-fold higher and the cardiovascular mortality ratio was 5-fold higher in cancer survivors than in the general population. In another large study 60 that compared childhood cancer survivors with their siblings, the cumulative incidence of coronary artery disease, CHF, valvular disease, and arrhythmia in survivors by age 45 years was much higher than those found in their siblings. Cancer therapy greatly accelerates the development of cardiovascular diseases, which can be reduced by lowering the intensity of radiation therapy and anthracycline exposure. 61 Further improvement in quality of life in cancer survivors can be achieved through exercise, weight control, dietary discretion, and complementary medicine. 62 Recent advances in oncology are rapidly developing personalized cancer therapies based on the identification of driver mutations and the application of targeted therapy. We may be able to identify the driver mutations that cause cardiotoxic effects in susceptible individuals to make decisions on anticancer drug choices. For example, patients with high topoisomerase 2β levels in peripheral blood may be more susceptible to anthracycline-induced cardiotoxic effects. In these high-risk patients, we can consider nonanthracycline alternatives or provide early cardioprotection with dexrazoxane. With better understanding of the genetics of dilated cardiomyopathies, we may consider patients with positive family history or with susceptible genes to be at high risk for developing cancer therapy-induced cardiotoxic effects. These patients should be monitored closely and treated with less aggressive radiation or chemotherapy. These are exciting challenges and opportunities that will test the ingenuity and persistence of the next generation of oncocardiologists.
